Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 601–700 of 2,656
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
Tanaka, A., Shibata, H., Imai, T., Yoshida, H., Miyazono, M., Takahashi, N., Fukuda, D., Okada, Y., Teragawa, H., Suwa, S., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01928-y · Cited by 13
Reducing the gap of chronic kidney disease in low- and middle-income countries: what is missing?
López-Delgado, D. S., Vargas, J. A. H., Urina-Jassir, M., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100625 · Cited by 12
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Taheri, S. (2023) · World Journal of Nephrology · doi:10.5527/wjn.v12.i5.182 · Cited by 14
Jarraya, F., Niang, A., Bagha, H., Tannor, E. K., Sumaili, E. K., Wan, D. I. M., Chothia, M., Mengistu, Y. T., Kaze, F. F., Ulasi, I., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.019 · Cited by 15
Rhee, J. J., Han, J., Montez‐Rath, M. E., & Chertow, G. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15427 · Cited by 17
“8 In contrast, ertugliflozin was non-inferior to placebo in the VERTIS-CV trial with regards to MACE but did not show superiority with respect to cardiovascular or renal outcome patients with T2DM and established atherosclerotic disease.”
ResultGRP78 Contributes to the Beneficial Effects of SGLT2 Inhibitor on Proximal Tubular Cells in DKD
Nakatsuka, A., Yamaguchi, S., & Wada, J. (2024) · Diabetes · doi:10.2337/db23-0581 · Cited by 12
Bhatt, A. S., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Anand, I. S., Desai, A. S., Fang, J. C.-T., Hernandez, A. F., Jhund, P. S., Kosiborod, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032279 · Cited by 18
Nakhleh, A., Abdul‐Ghani, M. A., Gazit, S., Gross, A., Livnat, I., Greenbloom, M., Yarden, A., Khazim, K., Shehadeh, N., & Cohen, C. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15623 · Cited by 16
Limonte, C. P., Lamprea-Montealegre, J. A., & Tuttle, K. R. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151520 · Cited by 14
Metabolism and bioenergetics in the pathophysiology of organ fibrosis
Miguel, V., Alcalde‐Estévez, E., Sirera, B., Rodríguez‐Pascual, F., & Lamas, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.001 · Cited by 13
Marques, P. S., Mavrakanas, T. A., Guida, J., Gédéon, T., Emami, A., Alaamiri, A., Ho, D., Possik, E., Zhang, G. K., Tsoukas, M. A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15691 · Cited by 13
Use of Sodium–Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
Ünlü, O., Bhatt, A. S., & Blood, A. J. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101024 · Cited by 14
Khani, E., Aslanabadi, N., Mehravani, K., Rezaei, H., Afsharirad, H., & Entezari‐Maleki, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00662-4 · Cited by 12
“Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to decrease all-cause mortality and improve cardiovascular outcomes in patients with chronic heart failure (HF) and chronic kidney disease (CKD), irrespective of type 2 diabetes mellitus status [1, 2].”
FITCHETT, D. H., Zinman, B., Inzucchi, S. E., Wanner, C., Anker, S. D., Pocock, S., Mattheus, M., Vedin, O., & Lund, S. S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02328-6 · Cited by 14
Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review
Lahane, G. P., Dhar, A., & Bhat, A. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23795 · Cited by 14
Karreci, E. S., Jacas, S., Donovan, O., Pintye, D., Wiley, N., Zsengellér, Z. K., Schlöndorff, J. S., Alper, S. L., Friedman, D. J., & Pollak, M. R. (2024) · Kidney International · doi:10.1016/j.kint.2024.07.026 · Cited by 13
Zou, X., Shi, Q., Vandvik, P. O., Mao, Y., Agarwal, A., Ponte, B., Zeng, X., Guyatt, G. H., Yang, Q., Luo, X., et al. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2024-001009 · Cited by 16
Spiazzi, B. F., Piccoli, G. F., Wayerbacher, L. F., Lubianca, J. P. N., Scalco, B. G., Scheffler, M. H., Fraga, B. L., Colpani, V., & Gerchman, F. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111933 · Cited by 16
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Kim, J. H., Lee, J., Han, K., Kim, J., & Kwon, H. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0275 · Cited by 13
Pearce, L., Galán‐Arriola, C., Bell, R., Carr, R. D., Cunningham, J., Davidson, S. M., Ghosh, A. K., Giesz, S., Golforoush, P. A., Gourine, A. V., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01094-6 · Cited by 16
Hosseini, Z. S., Jamili, M. J., Ensan, B., Donyadideh, G., Shahri, B., Eshraghi, H., Darroudi, S., & Moohebati, M. (2025) · Scientific Reports · doi:10.1038/s41598-024-82991-7 · Cited by 14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 18
Sagy, I., Shitrit, I. B., Abuhasira, R., David, R. B., Haviv, Y. S., Tayer-Shifman, O. E., Abu‐Shakra, M., Brav, E., Burrack, N., & Zeller, L. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152746 · Cited by 17
Eswarappa, M. S., Madden, E., Shlipak, M. G., Cui, X., Mrug, M. M., Estrella, M. M., & Park, M. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000725 · Cited by 13
Cardiometabolic Dysregulation and Heart Failure
Ashfield, S., & Ojha, U. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38504 · Cited by 15
Lui, D. T. W., Wu, T., Tang, E. H. M., Au, I. C. H., Lee, C., Woo, Y. C., Tan, K. C. B., & Wong, C. K. H. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110576 · Cited by 12
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 14
Combination Diuretic Therapy to Counter Renal Sodium Avidity in Acute Heart Failure
Kazory, A. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000188 · Cited by 16
Belančić, A., & Majanović, S. K. (2023) · Diabetology · doi:10.3390/diabetology4030022 · Cited by 15
Berezina, T. A., Fushtey, I. M., Berezin, A. A., Pavlov, S. V., & Berezin, A. Е. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02683-y · Cited by 13
Bauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
Janota, O., Mantovani, M., Irlik, K., Kwiendacz, H., Olejarz, A., Pabis, P., Włosowicz, A., Piaśnik, J., Wójcik, W., Szromek‐Białek, P., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02852-z · Cited by 15
SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art
Minutolo, R., Ruotolo, C., Conte, G., & Borrelli, S. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf350 · Cited by 16
van der Hoek, S., Jongs, N., Oshima, M., Neuen, B. L., Stevens, J., Perkovic, V., Levin, A., Mahaffey, K. W., Pollock, C. A., Greene, T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000161 · Cited by 12
“N 650 1406 1849 494 Age, yr 64 (9) 64 (9) 62 (9) 61 (9) Male, n (%) 475 (73) 966 (69) 1212 (66) 252 (51) Race, n (%) Asian 158 (24) 289 (21) 336 (18) 94 (19) Black 29 (5) 63 (5) 105 (6) 27 (6) Other 56 (9) 104 (7) 160 (9) 49 (10) White 407 (63) 950 (68) 1248 (68) 324 (66) Current smoker, n (%) 85 (13) 224 (16) 279 (15…”
Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
Vervloet, M. G. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad112 · Cited by 11
Stompór, T. P., Adamczak, M., Kurnatowska, I., Naumnik, B., Nowicki, M. P., Tylicki, L., Winiarska, A., & Krajewska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165184 · Cited by 20
Goldman, J. D., Busch, R. S., & Miller, E. M. (2024) · Clinical Diabetes · doi:10.2337/cd23-0074 · Cited by 19
van der Pluijm, L. A. K., Koudijs, A., Stam, W., et al. (2024) · Acta Physiologica · doi:10.1111/apha.14108 · Cited by 11
Cho, J.-H., Doo, S. W., Song, N., Lee, M., Lee, H., Kim, H., Jeon, J. S., Noh, H., & Kwon, S. H. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3237 · Cited by 11
Muta, Y., Kobayashi, K., Toyoda, M., Tone, A., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., Takeda, H., Yokomizo, H., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1358573 · Cited by 11
Hojná, S., Malínská, H., Hüttl, M., Vaňourková, Z., Marková, I., Miklánková, D., Hrdlička, J., Papoušek, F., Neckář, J., Kujal, P., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116520 · Cited by 11
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S. A., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 13
Are there lost opportunities in chronic kidney disease? A region-wide cohort study
Sundström, J., Norhammar, A., Karayiannides, S., Bodegård, J., Gustafsson, S., Cars, T., Svensson, M. K. E., & Ärnlöv, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074064 · Cited by 14
Matsuda, K., Mitsuo, H., Nishijima, T., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0864 · Cited by 11
Bonacchi, G., Rossi, V. A., Garofalo, M., Mollace, R., Uccello, G., Pieragnoli, P., Checchi, L., Perrotta, L., Voltolini, L., Ricciardi, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050981 · Cited by 14
Chan, M., & Liu, K. D. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151515 · Cited by 15
Osataphan, N., Abdel-Qadir, H. M., Zebrowska, A. M., & Borowiec, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01577-8 · Cited by 11
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
Vasco, M. A. E., Fantaye, S. H., Raghunathan, S., & Solis‐Herrera, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15773 · Cited by 13
Zachariah, T. P., & Radhakrishnan, J. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000540 · Cited by 13
Evidence based treatment for lupus nephritis: present perspectives and challenges
Xagas, E., Drouzas, K., Liapis, G., & Lionaki, S. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2024.1417026 · Cited by 13
Neuen, B. L., Ostrominski, J. W., Claggett, B. L., Beldhuis, I. E., Chatur, S., McCausland, F. R., Badve, S. V., Arnott, C. G., Heerspink, H. J. L., Jun, M., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.006 · Cited by 11
Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD
Deo, R., Dubin, R. F., Ren, Y., Wang, J., Feldman, H. I., Shou, H., Coresh, J., Grams, M. E., Surapaneni, A., Cohen, J. B., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000502 · Cited by 11
When to Start Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis
Cusick, M. M., Tisdale, R. L., Chertow, G. M., Owens, D. K., Goldhaber‐Fiebert, J. D., & Salomon, J. A. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.3892 · Cited by 14
Chuang, W.-L., Tsai, S. C., Yang, Y., Hsieh, T.-L., Lin, H.-J., Huang, Y., Tsai, F., & Chang, K. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03660-0 · Cited by 14
Liabeuf, S., Minutolo, R., Floege, J., & Zoccali, C. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae380 · Cited by 21
Brock, C., Andersen, H., Alibegovic, A. C., Andersen, S. R. D., Andreasen, L., Charles, M., Christensen, D. H., Drewes, A. M., Gall, M.-A., Gylfadottir, S. S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112010 · Cited by 12
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study
Lindhardt, M. K., Knudsen, S. T., Saxild, T., Charles, M., & Borg, R. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02721-4 · Cited by 19
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
Patel, T., Zheng, H., & Patel, K. P. (2025) · Antioxidants · doi:10.3390/antiox14030336 · Cited by 10
Yen, F., Hsu, C., Yeh, Y., Cheng, W.-Y., Liao, P., Hwu, C., & Wei, J. C. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.03.019 · Cited by 12
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy
Glassock, R. J. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03187-7 · Cited by 14
Soliman, A. R., El-Khatib, M., Khashab, S., Darwish, R. A., Fayed, A., Abdelaziz, T. S., Hammad, H., Ahmed, R. M., & Maamoun, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01790-w · Cited by 15
“Several ongoing trials seek to further elucidate the role of SGLT2is in KTRs. Additionally, in the DAPA-CKD and EMPA-KIDNEY trials [6, 78], preliminary findings revealed reductions in HbA1c, weight, and proteinuria, providing a foundation for assessing renoprotective and cardiovascular benefits.”
Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
Zhang, B., & Deng, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1574693 · Cited by 24
“Although final data have not been fully released, the existing preliminary results already show significant efficacy of Empagliflozin in both diabetic and non-diabetic patients, particularly in terms of kidney and cardiovascular protection (83).”
Hong, B., Lee, H., Jung, K., Rhee, S. Y., Yon, D. K., & Shin, J. (2025) · BMJ · doi:10.1136/bmj-2025-085196 · Cited by 13
mTOR signaling in renal ion transport
Adella, A., & de Baaij, J. H. F. (2023) · Acta Physiologica · doi:10.1111/apha.13960 · Cited by 14
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Birkenfeld, A. L., Ceriello, A., CHENG, A. Y. Y., Davies, M. J., Edelman, S. V., Forst, T. M., Giorgino, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01788-6 · Cited by 13
“In 2022, the list of outcomes trials was expanded by two trials with SGLT2i: one in individuals with HF and preserved ejection fraction (HFpEF) with or without diabetes (DELIVER, with dapagliflozin) [28] and one evaluating the efficacy and safety on the progression of kidney disease and CVD in individuals with CKD (EM…”
BackgroundMethodSodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
Moady, G., Gal, T. B., & Atar, S. (2023) · Life · doi:10.3390/life13061256 · Cited by 12
“Besides the cardiovascular benefits, SGLT2 inhibitors also had renal-protective properties, as demonstrated in the DAPA-CKD, EMPA-KIDNEY trials [12,13].”
BackgroundTreatment of Fabry Nephropathy: A Literature Review
Shimohata, H., Yamashita, M., Yamada, K., et al. (2023) · Medicina · doi:10.3390/medicina59081478 · Cited by 11
“, dapagliflozin [56] and empagliflozin [57], sacubitril-valsartan [58], and a non-steroidal mineralocorticoid receptor antagonist, finerenone [59], have exhibited excellent reno-protective effects against CKD in individuals with diabetes and have received attention as attractive treatment options for CKD.”
BackgroundManagement of type 2 diabetes in the new era
Liakos, A., Karagiannis, T., Avgerinos, I., Malandris, K., Τσάπας, Α., & Bekiari, E. (2023) · HORMONES · doi:10.1007/s42000-023-00488-w · Cited by 13
Singh, P. K., Goyal, L., Mallick, D. C., Surani, S., & Yashi, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196202 · Cited by 13
Taguchi, S., Azushima, K., Yamaji, T., Suzuki, T., Abe, E., Tanaka, S., Hirota, K., Tsukamoto, S., Morita, R., Kobayashi, R., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01496-4 · Cited by 11
Yoshida, M., Nakashima, A., Ishiuchi, N., Miyasako, K., Morimoto, K., Tanaka, Y., Sasaki, K., Maeda, S., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316920 · Cited by 12
Doi, Y., Shinzawa, M., Arisato, T., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02467-w · Cited by 11
“On the contrary, emerging data indicate that the cardiovascular and kidney benefits of SGLT2 inhibitors do not wane even as the estimated glomerular filtration rate (eGFR) declines at least in patients with eGFR ≥ 20 mL/min/1.73 m 2 [16, 17].”
BackgroundInfluentialSato, A., & Nishimoto, M. (2025) · Hypertension Research · doi:10.1038/s41440-025-02175-2 · Cited by 14
Haider, S. H., Irfan, A., Sheikh, S. M., Larik, M. O., Raza, A., & Khabir, Y. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468251347777 · Cited by 12
“In the EMPA-KIDNEY trial, Herrington et al 58 reported that the renal benefit was most pronounced in patients with eGFR 60 ml/min/1.73 m², indicating a limitation in broader applicability.”
InfluentialWallace, H., Wick, J., Neuen, B. L., Buizen, L., Badve, S. V., Chalmers, J. P., Costa, J. D. O., Falster, M. O., Ha, J. T. K., Jardine, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16608 · Cited by 9
“…in prescription based on trial inclusion criteria, a CKD trial target population subgroup was identified among patients with guideline defined CKD (as per the SGLT2 inhibitor 4,18 – 20 and GLP1-RA 3 kidney outcome trial inclusion criteria), assessed on eGFR and UACR measurements recorded in 2019.”
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 17
Role of hypertension in progression of pediatric CKD
Mitsnefes, M. M., & Wühl, E. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-05894-1 · Cited by 11
Wahinya, M., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.37388 · Cited by 13
“DOI 10.7759/cureus.37388 7 of 12 Patient characteristics EMPAREG OUTCOME [19] CANVAS [20] DECLARE TIMI 58 [21] VERTIS-CV [22] CREDENCE [23] DAPA-CKD [24] SCORED [25] EMPA- KIDNEY [29] Mean age (years) 63 63 64 64 62 61 69 (median) 64 Gender (male) 71% 65% 63% 70% 66% 68% 55% 67% Ethnicity White 72% 78% 79% 87% 66% 50%…”
BackgroundMethodResultInfluentialOrtíz, A., Arroyo, R. A., Escribano, P. P. C., Fernández‐Fernández, B., Debén, F. M., Mediavilla, J. D., Doña, A. M., Soler, M. J., & Górriz, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2213888 · Cited by 12
“Despite that, a substantial proportion of patients with CKD treated with SLGT-2 inhibitors on top of RAS inhibitors exhibit CKD progression [7,8,40].”
BackgroundRenal Oxygen Demand and Nephron Function: Is Glucose a Friend or Foe?
Gronda, E., Iacoviello, M., Palazzuoli, A., Benevenuto, M., Gabrielli, D., & Arduini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129957 · Cited by 18
Dapagliflozin versus empagliflozin in patients with chronic kidney disease
Alnsasra, H., Tsaban, G., Solomon, A., Khalil, F. M., Aboalhasan, E., Azab, A. N., Azuri, J., Hammerman, A., & Arbel, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1227199 · Cited by 10
Hachuła, M., Kosowski, M., Basiak, M., & Okopień, B. (2023) · Pharmaceuticals · doi:10.3390/ph16091190 · Cited by 10
Hammer, A., Hofer, F., Kazem, N., Koller, L., Steinacher, E., Baumer, U., Wollmann, F., Kautzky‐Willer, A., Beitl, K., Remer, F., et al. (2023) · Journal of Women s Health · doi:10.1089/jwh.2023.0059 · Cited by 10
Theodorakopoulou, M. P., Alexandrou, M. E., Tsitouridis, A., Kamperidis, V., Pella, E., Xanthopoulos, A. V., Ziakas, A., Triposkiadis, F. K., Vassilikos, V. P., Papagianni, A. A., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae003 · Cited by 11
Yang, Y., Kim, N. H., Baek, J. H., Ko, S., Son, J. W., Lee, S., Rhee, S. Y., Kim, S., Sohn, T. S., Jun, J. E., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0225 · Cited by 11
Ooi, Y., Sarvanandan, T., Hee, N. K. Y., Lim, Q., Paramasivam, S. S., Ratnasingam, J., Vethakkan, S. R., Lim, S. K., & Lim, L. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0244 · Cited by 12
Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
Neumiller, J. J., Peter, W. L. S., & Shubrook, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051367 · Cited by 16
“The 2023 American Diabetes Association (ADA) Standards of Care and the 2022 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for diabetes management in CKD recommend early diagnosis and multifactorial management of patients with T2D and CKD (Figure 1), including lifestyle interventions,…”
BackgroundInfluentialHaris, M., Raveendra, K., Travlos, C. K., Lewington, A. J. P., Wu, J., Shuweihdi, F., Nadarajah, R., & Gale, C. P. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae098 · Cited by 14
“Multiple randomized controlled trials have demonstrated that novel treatment options and appropriate management of risk factors reduce disease progression and mortality for patients with CKD [34 –36 ].”
BackgroundExplaining Alport syndrome—lessons from the adult nephrology clinic
Mabillard, H. R., Ryan, R., Tzoumas, N., et al. (2024) · Journal of Rare Diseases · doi:10.1007/s44162-024-00036-z · Cited by 10
“Similarly to DAPA-CKD, the EMPA-KIDNEY trial showed equally opti-misitic results with Empagliflozin (an SGLT2-inhibitor) and included 6609 people with CKD of which many people living with Alport syndrome were included although Alport-specific data disappointingly remains unpublished [55].”
ResultMreyoud, H., Walter, K. S., Wilpula, E., & Park, J. M. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2928 · Cited by 12
Kitaoka, K., Yano, Y., Nagasu, H., Kanegae, H., Chishima, N., Akiyama, H., Tamura, K., & Kashihara, N. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004115 · Cited by 15
New perspectives in the management of diabetic nephropathy
Psyllaki, A., & Τζιόμαλος, Κ. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1086 · Cited by 12
Wang, Q., Yu, J., Deng, W., Liu, C., Yang, J., Li, Y., Cai, G., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372421 · Cited by 15
Fusagawa, H., Sato, T., Yamada, T., Naito, A., Tokuda, N., Yamauchi, N., Ichise, N., Ogawa, T., Karaushi, T., Teramoto, A., et al. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1423504 · Cited by 11
Fano, M. D., Falorni, A., Malara, M., Porcellati, F., & Fanelli, C. G. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s466328 · Cited by 14
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.